Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 501

1.

Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.

Créange A, Debouverie M, Jaillon-Rivière V, Taithe F, Liban D, Moutereau A, Clavelou P, Defer G.

Mult Scler. 2009 Sep;15(9):1085-91. doi: 10.1177/1352458509106710. Epub 2009 Jun 25.

PMID:
19556312
2.

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.

Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.

BMC Neurol. 2006 May 23;6:19.

3.

[Hospital-at-home as a solution for the treatment requirements of acute exacerbation in multiple sclerosis].

Steinmetz D, Edelstein H, Dishon S, Berkovitz E, Almany A, Miller A.

Harefuah. 2001 Jul;140(7):603-6, 678. Hebrew.

PMID:
11481961
4.

The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.

Sharrack B, Hughes RA, Morris RW, Soudain S, Wade-Jones O, Barnes D, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi HA, Farmer S, Frankel JP.

J Neurol Sci. 2000 Feb 1;173(1):73-7.

PMID:
10675582
5.

Cost analysis of methylprednisolone treatment of multiple sclerosis patients.

Robson LS, Bain C, Beck S, Guthrie S, Coyte PC, O'Connor P.

Can J Neurol Sci. 1998 Aug;25(3):222-9.

PMID:
9706724
6.

[Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].

Pascual AM, Boscá I, Escutia M, Bernat A, Coret F, Casanova B.

Neurologia. 2008 Mar;23(2):73-7. Spanish.

PMID:
17641984
7.

Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.

Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.

J Neurol Sci. 2008 Apr 15;267(1-2):28-35. Epub 2007 Oct 18.

PMID:
17945260
8.

Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.

Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J, Thompson A.

Lancet Neurol. 2006 Jul;5(7):565-71. Erratum in: Lancet Neurol. 2006 Jul;5(7):555.

PMID:
16781986
9.
10.

It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.

McNicholas N, Patel A, Chataway J.

QJM. 2012 Aug;105(8):775-80. doi: 10.1093/qjmed/hcs070. Epub 2012 Apr 17.

PMID:
22514268
11.

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience.

Lancet. 2015 Sep 5;386(9997):974-81. doi: 10.1016/S0140-6736(15)61137-0. Epub 2015 Jun 28. Erratum in: Lancet. 2016 Jan 23;387(10016):340.

12.

A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS).

Riazi A, Porter B, Chataway J, Thompson AJ, Hobart JC.

Health Qual Life Outcomes. 2011 Sep 26;9:80. doi: 10.1186/1477-7525-9-80.

13.

[Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis].

Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J.

Ugeskr Laeger. 1999 Nov 29;161(48):6625-9. Danish.

PMID:
10643347
14.

Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.

Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E.

Acta Neurol Scand. 2002 Mar;105(3):164-8.

PMID:
11886358
15.

Cost of managing an episode of relapse in multiple sclerosis in the United States.

O'Brien JA, Ward AJ, Patrick AR, Caro J.

BMC Health Serv Res. 2003 Sep 2;3(1):17.

16.
17.

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group.

Neurology. 2004 Dec 14;63(11):2028-33.

PMID:
15596745
18.

Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis.

Habek M, Barun B, Puretić Z, Brinar VV.

Ther Apher Dial. 2010 Jun;14(3):298-302. doi: 10.1111/j.1744-9987.2009.00794.x.

PMID:
20609182
19.

Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis.

van Winsen LM, Polman CH, Dijkstra CD, Tilders FJ, Uitdehaag BM.

Mult Scler. 2010 Apr;16(4):500-2. doi: 10.1177/1352458509359721. Epub 2010 Jan 19.

PMID:
20086025
20.

[Natalizumab (Tysabri) prescription practices of neurologists in southern France].

Rocher F, Cohen M, Lebrun C.

Rev Neurol (Paris). 2010 Apr;166(4):412-8. doi: 10.1016/j.neurol.2009.09.008. Epub 2009 Oct 28. French.

PMID:
19846185

Supplemental Content

Support Center